Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NCM · Healthcare · Biotechnology
$8.19
+5.27%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$151.7M
Shares Outstanding
18.5M
Exchange
NCM
Currency
USD
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -19.2M | -24.4M | -22.0M | -24.3M |
| Net Income | -17.7M | -23.3M | -20.6M | -23.0M |
| Diluted EPS | $-1.44 | $-1.90 | $-1.25 | $-1.23 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -34.8M | -45.1M | -48.7M | -85.3M |
| Net Income | -42.3M | -44.6M | -40.2M | -78.5M |
| Diluted EPS | $-10.15 | $-10.31 | $-3.68 | $-5.90 |